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Despite effective therapies for smoking cessation, most smokers find quitting difficult and most successful quitters relapse. Considerable
evidence supports a genetic risk for nicotine dependence; however, less is known about the pharmacogenetics of smoking cessation. In the
first pharmacogenetic investigation of the efficacy of varenicline and bupropion, we examined whether genes important in the
pharmacodynamics and pharmacokinetics of these drugs and nicotine predict medication efficacy and adverse events. Subjects participated
in randomized, double-blind, placebo-controlled smoking cessation clinical trials, comparing varenicline, a nicotinic acetylcholine receptor
(nAChR) partial agonist, with bupropion, a norepinephrine/dopamine reuptake inhibitor, and placebo. Primary analysis included 1175
smokers of European ancestry, and 785 single nucleotide polymorphisms from 24 genes, representing 254 linkage disequilibrium (LD) bins
(genes included nAChR subunits, additional varenicline-specific genes, and genes involved in nicotine or bupropion metabolism).
For varenicline, continuous abstinence (weeks 9–12) was associated with multiple nAChR subunit genes (including CHRNB2, CHRNA5,
and CHRNA4) (OR¼1.76; 95% CI: 1.23–2.52) (po0.005); for bupropion, abstinence was associated with CYP2B6 (OR¼1.78; 95% CI:
1.27–2.50) (po0.001). Incidence of nausea was associated with several nAChR subunit genes (OR¼0.50; 95% CI: 0.36–0.70)
(po0.0001) and time to relapse after quitting was associated with HTR3B (HR¼1.97; 95% CI: 1.45–2.68) (po0.0001). These data
provide evidence for multiple genetic loci contributing to smoking cessation and therapeutic response. Different loci are associated with
varenicline vs bupropion response, suggesting that additional research may identify clinically useful markers to guide treatment decisions.
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INTRODUCTION
Nicotine dependence is a chronic, relapsing addiction
(Lerman et al, 2007), that afflicts 420% of the popula-
tion worldwide (Fiore et al, 2008). Nicotine exerts its
effect primarily at heterogeneous acetylcholine receptors
(nAChRs) in the brain. This activity stimulates dopaminer-
gic and other pathways and this increase in dopamine
contributes to the rewarding effects of nicotine (Dani and
Heinemann, 1996). The principal subtypes of these penta-
meric receptors include a4 and b2 subunits, sometimes
complimented by additional subunits of a different type
(eg, a5) (Mineur and Picciotto, 2008; Ray et al, 2010).
Nicotine shows high affinity for a4b2-containing nicotinic
receptors, with Ki values in the low nanomolar range (Gotti
et al, 2006).
The persistence of smoking can be attributed to multiple
diverse causes. Chief among these are genetic risk factors
contributing to smoking behavior (Li et al, 2003; Maes et al,
2004; Sullivan and Kendler, 1999; The Tobacco and Genetics
Consortium, 2010). Genome-wide association studies
(GWAS) have identified a primary genetic locus on chromo-
some 15q25 that increases the likelihood of nicotine
dependence by 30–40% in individuals who carry common
risk alleles (Amos et al, 2008; Hung et al, 2008; Thorgeirs-
son et al, 2008), as well as increasing the risk for several
smoking-related diseases (Broderick et al, 2009; Landi et al,
2009; Pillai et al, 2009; Thorgeirsson et al, 2008). This locus
includes three nicotinic receptor subunit genes (CHRNA5,
CHRNB4, and CHRNA3), and a gene expressed in the lungs
(IREB2), any (or several) of which may contain variants
that contribute to nicotine dependence risk (DeMeo et al,
2009). Indeed, evidence points to the presence of multiple
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pendence (Saccone et al, 2010a,b). GWAS meta-analyses
have identified four additional loci associated with nicotine
dependence (The Tobacco and Genetics Consortium, 2010;
Thorgeirsson et al, 2010). Two of these loci map close
to additional nicotinic receptor subunits (CHRNA6 and
CHRNB3) and to enzymes important for the metabolism of
nicotine (CYP2A6 and CYP2B6).
An additional factor in the persistence of smoking
behaviors is the difficulty in quitting. Although many
methods have been developed that improve quit rates, none
is effective in all smokers (Lerman et al, 2007). Among these
methods are several pharmacological agents, including
nicotine replacement therapy (NRT), bupropion, and vareni-
cline. Bupropion is a dopamine/norepinephrine reuptake
inhibitor that also acts as a nicotinic receptor antagonist
(Warner and Shoaib, 2005); varenicline is a partial agonist of
the a4b2n A C h Rs u b t y p e( C o eet al, 2005). The determinants
of successful smoking cessation, like nicotine dependence
itself, are likely to be diverse. The genetic components of
successful smoking cessation are less well understood than
nicotine dependence itself, although, like nicotine depen-
dence, a significant proportion (B50%) of the likelihood of
quitting is genetic in origin (Broms et al, 2006; Lessov et al,
2004; Xian et al, 2003), suggesting that specific genetic risk
factors could be identified. Indeed, the chromosome 15q25
locus described above has been associated with successful
quitting in pregnant women (Freathy et al, 2009). However,
many of the genetic loci affecting quitting are likely to be
distinct from genetic determinants of nicotine dependence
(Maes et al, 2004; The Tobacco and Genetics Consortium,
2010; Thorgeirsson et al, 2010).
In order to better understand the genetic determinants
of smoking cessation, recent pharmacogenetic studies have
investigated genes that may impact nicotine or bupropion
activity and metabolism, and also components of the
dopaminergic system related to addiction (Conti et al,
2008; Kortmann et al, 2010; Lee et al, 2007; Ray et al,
2010). Although replications are needed, variants identi-
fied in CYP2B6 and CHRNB2 may influence cessation rates
for bupropion (Conti et al, 2008; Lee et al, 2007), and
variants in the choline acetyltransferase (CHAT) gene may
influence the success of NRT (Ray et al, 2010). In addi-
tion, several pharmacogenomics studies have investigated
the effect of nicotine metabolism rates directly, through
analysis of nicotine metabolites (Benowitz, 2009) with
reproducible associations with smoking cessation (Ray
et al, 2009).
Here, we describe the first pharmacogenetic analysis of
smoking cessation in a large population of smokers derived
from placebo-controlled clinical trials testing the efficacy
of varenicline and bupropion. In addition to drug meta-
bolizing and nicotinic receptor genes, we investigated
the primary varenicline transporter (SLC22A2), additional
genes in the chromosome 15q25 locus (IREB2, LOC123688,
and PSMA4), and two serotonin receptors (HTR3A and
HTR3B) whose expression in the gut may contribute to
nausea while on varenicline treatment (Gershon, 2004). We
also examined whether variation in these candidate genes is
associated with time to relapse to smoking or to nausea
while on treatment.
PATIENTS AND METHODS
Study Population
Subjects included in this study had participated in one
of three randomized, double-blind, placebo-controlled
smoking cessation clinical trials comparing varenicline, a
nAChR partial agonist, with bupropion, a norepinephrine
and dopamine reuptake inhibitor, and placebo (Box 1).
The three trials have been described in detail previously
Box 1 Varenicline Clinical Studies Included in the Pharmacogenetics Analysis
Design Length Patients
Jorenby et al (2006) Randomized, double-blind,
parallel-group, placebo- and
active-treatment-controlled
12 Weeks, with 40 weeks of non-drug
follow-up
1027 Randomized:
varenicline 1.0mg twice per day, titrated during week 1
(n¼344)
bupropion SR 150mg twice per day, titrated during
week 1 (n¼342)
placebo (n¼341)
Gonzales et al (2006) Randomized, double-blind,
parallel-group, placebo- and
active-treatment-controlled
12 Weeks, with 40 weeks of non-drug
follow-up
1025 Randomized:
varenicline 1.0mg twice per day, titrated during week 1
(n¼352)
bupropion SR 150mg twice per day, titrated during
week 1 (n¼329)
placebo (n¼344)
Oncken et al (2006) Randomized, double-blind,
multicenter, placebo-controlled
12 Weeks, with 40 weeks of non-drug
follow-up
647 Randomized
a:
varenicline 0.5mg twice per day non-titrated
(n¼129)
varenicline 0.5mg twice per day titrated (n¼130)
varenicline 1.0mg twice per day non-titrated
(n¼129)
varenicline 1.0mg twice per day titrated (n¼130)
placebo (n¼129)
aFor the pharmacogenetics study, the varenicline subjects from this trial were limited to those who were randomized to the 1.0mg twice per day titrated dosing, in
order to match the varenicline dosing in the other clinical trials.
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Neuropsychopharmacology(Gonzales et al, 2006; Jorenby et al, 2006; Oncken et al,
2006). In brief, all of the studies included a 12-week treat-
ment period and 40-week non-treatment follow-up. Parti-
cipants were healthy men and women; all had smoked
an average of at least 10 cigarettes per day (CPD) during
the past year, with no period of abstinence longer than
3 months, and were motivated to quit. For these clinical
trials, patients were excluded if they had a history of alcohol
or other drug abuse or dependence in the previous 12
months. Clinical trial endpoints included carbon monoxide-
confirmed continuous abstinence from weeks 9 to 12 and
weeks 9 to 52 (Gonzales et al, 2006; Jorenby et al, 2006;
Oncken et al, 2006), and time to smoking relapse. Relapse to
smoking after abstinence from weeks 9 to 12 was indicated
either by patient-reported cigarette (as little as a single puff)
or other nicotine use, or by an expiratory carbon monoxide
measurement exceeding 10 p.p.m.
An optional blood sample was collected from clinical trial
subjects for pharmacogenetic analysis to investigate poten-
tial associations between genetic variants and varenicline
response and general characteristics of smoking cessation.
Sample collection was not required for participation in
the original clinical trials; however, 450% of clinical trial
subjects across all treatment arms volunteered to participate
in the pharmacogenetic analysis.
Genotyping
Candidate genes of interest included the genes identified on
Chr15q25 (including the CHRNA5, CHRNA3, and CHRNB4
gene cluster), the remaining nAChR subunit genes, genes
encoding the varenicline transporter (SLC22A2) and seroto-
nergic targets hypothesized to be involved in varenicline-
induced nausea (HTR3A, HTR3B), as well as cytochrome
P450 (CYP) genes involved in nicotine and bupropion
metabolism (Box 2). Varenicline is highly selective for the
a4b2 nicotinic receptor (Ki¼0.17nM) (Pfizer, 2010), but
also shows moderate affinity (Ki¼350nM) for the 5-HT3
receptor and other common nicotinic receptors.
Primary genotyping was performed on the Illumina
GoldenGate platform, with 975 candidate gene single-
nucleotide polymorphisms (SNPs) and 216 ancestry infor-
mative marker SNPs. In addition, 89 complementary SNPs
were genotyped using ABI Taqman and SNPlex methods.
Genotyping call rates for all samples were X94% (mean¼
99.8%; median¼99.8%). Genotyping call rates for all SNPs
were X97% (mean¼99.8%, median¼99.9%). SNPs were
tested for Hardy–Weinberg equilibrium. In total, 12 SNPs
were significantly out of HWE (po0.0001). None of these
were associated with any phenotypes tested here. Multi-
dimensional scaling analysis of the ancestry informative
markers identified four subjects that did not cluster with the
subjects of European ancestry. These subjects were excluded
from the analysis.
Statistical Analysis
Genetic associations for continuous abstinence rates and
nausea incidence were assessed using logistic regression,
assuming an additive genetic model. A survival model was
used to assess the relapse data; specifically, a proportional
hazards model was fitted to determine whether the time to
relapse was affected by genotype. The proportional hazards
assumption was checked using plots of the log-log survival
(relapse) curves. The relapse analysis also assumed an
additive genetic model. Our analysis was limited to SNPs
whose minor allele frequency was 45% in our overall geno-
typed population, reducing the total number of candidate
gene SNPs analyzed to 785. For each analysis, a treat-
ment genotype interaction term was initially included in
the model. For markers with at least marginally significant
interaction with treatment (po0.20), the analysis was
performed for each treatment group separately, as well as
for all subjects together and adjusted for treatment. When
the interaction was not significant, the data were analyzed
as a single pooled sample, adjusted for treatment. To correct
for multiple testing in which many markers were in strong
linkage disequilibrium (LD), we selected individual SNPs
representing bins of highly linked SNPs (r
240.8), with a
single SNP for each bin included in a false discovery rate,
multiple test correction approach (bins were derived from
the Caucasian population described here). This reduced the
total estimated number of independent tests from 785 to
254. All of the p-values reported here fell below a q-value of
0.2, using this approach.
RESULTS
Study Population
Across the three trials, 2699 patients were randomized to
treatment (including 826 to varenicline 1.0mg twice per day
titrated dose, 671 to bupropion, and 814 to placebo). DNA
was extracted from blood samples of 1476 consenting
individuals (524 varenicline; 440 bupropion; 512 placebo),
and primary genetic analysis was performed on 1175
smokers of European ancestry. The genotyped subset was
comparable to the overall clinical data set for baseline
characteristics and outcomes, including age, gender, race,
weight, smoking history, Fagerstro ¨m Test for Nicotine
Dependence, therapeutic smoking cessation response (con-
tinuous abstinence from weeks 9 to 12), and adverse event
profile (including nausea incidence with varenicline).
Baseline Characteristics
The demographic and smoking history characteristics of
genotyped participants from the three clinical trials are
Box 2 Candidate Gene List
Nicotine and bupropion metabolism CYP2A6, CYP2B6
Nicotinic receptors CHRNA1, CHRNA2, CHRNA3,
CHRNA4, CHRNA5, CHRNA6,
CHRNA7, CHRNA9, CHRNA10,
CHRNB1, CHRNB2, CHRNB3,
CHRNB4, CHRND, CHRNE, CHRNG
Varenicline transporter, additional
targets of varenicline
SLC22A2 (OCT8), HTR3A, HTR3B
Genes in linkage disequilibrium on
Chr15q25
IREB2, LOC123688, PSMA4
Genes shown in bold are within the LD region on Chr15q25 previously reported
to be associated with nicotine dependence.
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Neuropsychopharmacologyshown in Table 1. Patients in the analysis had a mean age of
approximately 43 years, and nearly 50% of the population
was female. They smoked on average 22 CPD (SD 9.4), and
an average score of 5.3 on the Fagerstro ¨m Test for Nicotine
Dependence (SD 2.1) indicated a moderate level of addic-
tion. There were no significant differences in demographic
variables or baseline characteristics across the three treat-
ment groups.
Analysis of baseline smoking behavior among all
genotyped subjects, as measured by the number of CPD,
revealed a genetic association with the primary nicotine
dependence locus on chromosome 15q25, indicating that
the population studied here is consistent with previous
populations evaluated for nicotine dependence (Thorgeirs-
son et al, 2008). The most significant SNP detected in this
region was rs4275821 (po0.003), although we also detected
nominal associations with other SNPs, including rs16969968
(po0.03). The CPD association with the 15q25 region was
detected in this population despite the absence of a full
range of smoking phenotypes (individuals smoking o10
CPD were excluded from the clinical trials) (Gonzales et al,
2006; Jorenby et al, 2006; Oncken et al, 2006). We also
detected an association between the 15q25 locus and scores
from the Fagerstro ¨m Test for Nicotine Dependence
(po0.004, rs12443170).
Continuous Abstinence
SNPs associated with continuous abstinence during weeks
9–12 of the treatment period are shown in Table 2. Among
the subjects randomized to varenicline treatment, two
polymorphisms in CHRNB2 (rs3811450 and rs4262952)
were associated with the largest increased odds of contin-
uous smoking abstinence from weeks 9 to 12 (OR¼2.52
(CI: 1.32–4.78); OR¼2.44 (CI: 1.28–4.63)). Additionally,
there were significant associations of SNPs within the
chromosome 15q25 locus, as well as the CHRNA4 and
CHRNA7 gene loci. The SNP most significantly associated
with continuous abstinence from weeks 9 to 12 in the
varenicline-treated smokers, rs7164594, is within the 15q25
locus and is in strong LD with rs2036534 (r
2¼0.98), a SNP
Table 1 Characteristics of Genotyped Patients from the Clinical
Trials
Varenicline Bupropion Placebo
Age (SD) 43.8 (11.1) 42.7 (12.0) 42.7 (11.9)
Gender, % male 52 56 57
Race, % Caucasian 82 82 79
Weight, kg (SD) 79.7 (16.2) 79.0 (15.9) 79.3 (15.6)
Smoking history, CPD (SD) 22.5 (9.9) 21.9 (8.7) 22.3 (9.7)
FTND total score (SD) 5.34 (2.2) 5.27 (2.1) 5.28 (2.0)
Abbreviations: CPD, cigarettes per day; FTND, Fagerstro ¨m Test for Nicotine
Dependence.
Table 2 Pharmacogenomics of Continuous Abstinence at Weeks 9–12
SNP MAF Gene Region Varenicline p-value OR 95% CI q-value
rs7164594 0.21 LOC123688 15q25 0.0019 1.76 1.23–2.52 0.181
rs3787138 0.13 CHRNA4 20q13 0.0030 1.89 1.24–2.88 0.181
rs6494212 0.30 CHRNA7 15q13 0.0038 1.58 1.16–2.15 0.181
rs3811450 0.07 CHRNB2 1q21 0.0048 2.52 1.32–4.78 0.181
rs2236196 0.27 CHRNA4 20q13 0.0063 1.54 1.13–2.09 0.181
rs4292956 0.07 CHRNB2 1q21 0.0067 2.44 1.28–4.63 0.181
rs518425 0.28 CHRNA5 15q25 0.0071 1.62 1.14–2.31 0.181
rs6062899 0.18 CHRNA4 20q13 0.0071 1.63 1.14–2.33 0.181
rs2938674 0.21 IREB2 15q25 0.0095 1.60 1.12–2.27 0.196
Bupropion p-value
rs8109525 0.34 CYP2B6 19q13 0.0008 1.78 1.27–2.50 0.120
rs3762528 0.07 CHRND 2q37 0.0012 2.98 1.54–5.77 0.120
rs1808682 0.25 CYP2B6 19q13 0.0030 1.70 1.20–2.41 0.154
rs6725786 0.10 CHRND 2q37 0.0036 2.23 1.30–3.84 0.154
rs1042389 0.20 CYP2B6 19q13 0.0038 1.90 1.23–2.92 0.154
rs2113103 0.16 CYP2B6 19q13 0.0049 1.82 1.20–2.76 0.167
Overall p-value
rs8109525 0.34 CYP2B6 19q13 0.0011 1.37 1.13–1.66 0.111
rs1808682 0.25 CYP2B6 19q13 0.0013 1.40 1.14–1.72 0.111
rs2014141 0.40 CYP2B6 19q13 0.0020 0.75 0.62–0.90 0.115
rs2113103 0.16 CYP2B6 19q13 0.0030 1.43 1.13–1.82 0.129
rs6010918 0.05 CHRNA4 20q13 0.0048 1.75 1.19–2.59 0.167
Abbreviations: CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; SNP, single-nucleotide polymorphism.
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Neuropsychopharmacologypreviously determined to be significantly associated with
lung cancer (Amos et al, 2008) (Figure 1a).
Among the bupropion-treated subjects and in all three
treatment groups combined, continuous abstinence at
weeks 9–12 was strongly associated with several SNPs in
CYP2B6 as well as two SNPs in CHRND, which encodes the
nAChR delta subunit. Interestingly, one of the CYP2B6
SNPs (rs8109525; Figure 1b) is contained within a LD
bin that includes rs7260329, a SNP recently identified to
be significantly associated with the number of cigarettes
smoked per day (Thorgeirsson et al, 2010). rs7260329 itself
is nominally associated with continuous abstinence in the
bupropion and combined populations, although to a lesser
degree (po0.008, po0.02, respectively; q values 40.2). No
SNP tested was significantly associated with abstinence on
placebo treatment.
During longer-term follow-up, through 52 weeks, no
polymorphism was significantly associated with continuous
abstinence in the varenicline or placebo treatment groups.
However, in the bupropion group, as well as in the three
treatment groups combined, continuous abstinence was
again associated with several SNPs within CYP2B6 (Table 3),
including rs8109525 (p¼0.0028, Figure 1b). Several of the
polymorphisms tested in CYP2B6 were in LD with this SNP
(including rs7260329, described above); however, none of
these linked SNPs correspond to functionally described
CYP2B6 alleles (Anon, 2008). In the combined treatment
group, variants in CYP2A6 were also significantly associated
with continued abstinence.
Relapse to Smoking, Following Successful Quitting,
All Treatments
For all treatment groups combined, time to smoking relapse
following initial abstinence from weeks 9–12 was associated
with SNPs in HTR3B (rs11606194, rs3758987) and HTR3A
(rs11607240) (Table 4). Figure 2 shows the time to relapse
associated with the two most predictive SNPs, rs11606194
and rs3758987.
Nausea
In these clinical trials, the adverse event most commonly
reported in patients receiving varenicline (1mg twice per
day) was nausea (Gonzales et al, 2006; Jorenby et al, 2006;
Oncken et al, 2006). Nausea was reported by 30% of
individuals in the varenicline group (ranging from 28%
to 35% across the three clinical trials) vs 10% in the
bupropion group, and 9% in the placebo group. The
incidence of nausea in the varenicline treatment group, and
in all three treatment groups combined, was associated
primarily with SNPs in the chromosome 15q25 locus
Figure 1 Genetic markers most significantly associated with continuous abstinence: (a) varenicline, (b) bupropion.
Table 3 Pharmacogenomics of Continuous Abstinence at Weeks 9–52
SNP MAF Gene Region Bupropion p-value OR 95% CI q-value
rs1808682 0.251 CYP2B6 19q13 0.00008 2.27 1.51–3.40 0.019
rs1042389 0.201 CYP2B6 19q13 0.0003 2.49 1.52–4.09 0.036
rs2113103 0.156 CYP2B6 19q13 0.0010 2.16 1.36–3.43 0.087
rs8100458 0.339 CYP2B6 19q13 0.0028 1.82 1.23–2.70 0.180
Overall p-value
rs1808682 0.251 CYP2B6 19q13 0.0001 1.58 1.25–1.99 0.019
rs11606194 0.076 HTR3B 11q23 0.0023 0.47 0.29–0.76 0.197
rs892216 0.348 CYP2B6 19q13 0.0042 1.37 1.11–1.70 0.197
rs7123164 0.115 CHRNA10 11p15 0.0050 1.55 1.14–2.11 0.197
rs7255616 0.067 CYP2A6 19q13 0.0057 1.69 1.16–2.45 0.197
Abbreviations: CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; SNP, single-nucleotide polymorphism.
rs8109525, shown in Figure 1, is in strong LD with both rs8100458 and rs892216 (r
240.95).
No SNPs were associated with continuous abstinence in patients receiving varenicline.
Pharmacogenetics of varenicline
DP King et al
645
Neuropsychopharmacology(Table 5 and Supplementary Table 1). Among varenicline-
treated patients, nausea was most significantly asso-
ciated with rs555018 in the CHRNA5 gene (OR¼1.62;
95% CI: 1.19–2.20) and rs1190449 in the CHRNG gene
(OR¼1.57; 95% CI: 1.18–2.08), while in the three treatment
groups combined, the most significant association was with
rs6495309 in the CHRNB4 gene (OR¼0.50; 95% CI: 0.36–
0.70; p¼4.04E–05).
DISCUSSION
This study represents the first genetic association study of
varenicline for smoking cessation. The pharmacogenetic
analysis, focusing largely on gene loci encoding nicotinic
cholinergic receptor subunits and drug metabolizing
enzymes, offers preliminary evidence that variants in
CHRNA4, CHRNB2, and CHRNA7 as well as in the 15q25
LD chromosomal region, including the nAChR genes
CHRNA3, CHRNA5, and CHRNB4, influence the outcome
(success or failure) of smoking cessation attempts with
varenicline. In contrast, genetic analysis of response to
bupropion suggests that the success of smoking cessation
with this drug is determined in part by variation
in CYP2B6, the gene encoding the primary enzyme
responsible for the metabolism of bupropion (Faucette
et al, 2000), rather than by genetic variation in nicotinic
cholinergic receptor pathways. In addition to smoking
cessation pharmacogenetics, we also evaluated pharma-
cogenetic associations with the presence of nausea while
attempting to quit smoking, as well as relapse to smoking
following a successful period of continuous abstinence. As
with response to varenicline, genetic variation in the nico-
tinic cholinergic receptor genes appears to contribute to the
risk of experiencing nausea during smoking cessation, and
interestingly, relapse to smoking was significantly associ-
ated with polymorphisms in the serotonergic receptor
genes, HTR3A and HTR3B.
Varenicline
Response to varenicline treatment is associated here
with polymorphisms in multiple loci encoding nicotinic
receptor subunits. Chief among these are the CHRNA4 and
CHRNB2 loci, encoding the a4 and b2 nicotinic receptor
subunits. Receptors comprised of these subunits are the
specific targets of varenicline’s activity, thus it is perhaps
not surprising that these loci would be associated with
varenicline response. In addition to these loci, there is
also an association to varenicline response with polymor-
phisms in the chr15q25 locus. This, too, is consistent with
varenicline activity, particularly given recent evidence
demonstrating the importance of a5 subunits in predomi-
nantly a4b2 nicotinic receptors and the emergence of risk
alleles in this locus as a primary factor in nicotine
Table 4 Loci Associated With Relapse During Weeks 12–52,
Among Those who had Successfully Quit at Weeks 9–12, All
Groups Combined (n¼420)
SNP MAF Gene Region p-value HR 95% CI q-value
rs11606194 0.076 HTR3B 11q23 1.53E–05 1.97 1.45–2.68 0.003
rs3758987 0.271 HTR3B 11q23 0.0006 1.46 1.18–1.81 0.049
rs11607240 0.074 HTR3A 11q23 0.0015 1.65 1.21–2.25 0.084
Abbreviations: CI, confidence interval; HR, hazard ratio; MAF, minor allele
frequency; SNP, single-nucleotide polymorphism.
Figure 2 Time to relapse among those who had successfully quit at weeks 9–12, all groups combined: (a) rs11606194, (b) rs3758987.
Table 5 Nausea Pharmacogenomics, Overall
SNP MAF Gene Region p-value OR 95% CI q-value
rs6495309 0.205 CHRNB4 15q25 4.04E–05 0.50 0.36–0.70 0.007
rs4887072 0.216 CHRNB4 15q25 0.0002 0.55 0.40–0.75 0.015
rs1878399 0.424 CHRNA3 15q25 0.0012 1.48 1.17–1.87 0.066
rs1190449 0.447 CHRNG 2q37 0.0021 1.42 1.13–1.77 0.092
rs6741278 0.369 CHRNG 2q37 0.0033 0.69 0.54–0.88 0.099
rs578776 0.273 CHRNA3 15q25 0.0039 0.67 0.51–0.88 0.099
rs595374 0.215 SLC22A2 6q25 0.0040 0.64 0.48–0.87 0.099
rs4243083 0.416 PSMA4 15q25 0.0049 1.40 1.11–1.77 0.105
rs684513 0.197 CHRNA5 15q25 0.0076 0.65 0.48–0.89 0.138
rs12899425 0.274 IREB2 15q25 0.0087 1.39 1.09–1.77 0.138
rs2869546 0.370 CHRNA3 15q25 0.0088 1.37 1.08–1.73 0.138
rs11899983 0.437 CHRNG 2q37 0.0113 1.34 1.07–1.68 0.157
rs17406522 0.072 IREB2 15q25 0.0125 1.67 1.12–2.50 0.157
rs12443170 0.126 CHRNA3 15q25 0.0128 0.62 0.42–0.90 0.157
rs12441998 0.199 CHRNB4 15q25 0.0151 0.68 0.50–0.93 0.173
Abbreviations: CI, confidence interval; OR, odds ratio; SNP, single-nucleotide
polymorphism.
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et al, 2011). An association between the 15q25 locus and
response to varenicline also supports an argument that
response to varenicline is related to nicotine dependence
itself. Due to the high degree of LD among loci in this
region, it is difficult to discriminate causative loci. The
positive markers for varenicline response are in LD (40.6)
with nicotine dependence markers (as well as markers for
nausea; see below), thus these associations may be reflecting
common functional alleles. In fact, the alleles that are
associated with increased odds of quitting with varenicline
are in LD with alleles associated with a decreased risk of
nicotine dependence. This may be true of bupropion and
placebo responders as well, although there are not sufficient
subjects in these groups to detect such an effect. The
relevance of the association with the CHRNA7 locus is less
clear, although varenicline does bind to homopentameric a7
nicotinic receptors (Coe et al, 2005), however with reduced
affinity in comparison with a4b2 receptors (Amos et al,
2008; Hung et al, 2008; Thorgeirsson et al, 2008).
Previous pharmacogenetic studies of smoking cessation,
focusing on bupropion treatment, also identified poly-
morphisms in CHRNB2 associated with treatment response.
In each of these studies, there is evidence to suggest that
response to treatment in the placebo group may also be
associated with CHRNB2, albeit to a lesser degree (Conti
et al, 2008; Heitjan et al, 2008; Perkins et al, 2009). In our
study, we detect a similar, nominal association in our
placebo group with a CHRNB2 SNP (rs2072659, p¼0.003,
q¼0.38). Thus, the genetic association of CHRNB2 with
response to varenicline might be explained in part by an
increased likelihood to quit, regardless of treatment.
Bupropion
In our study, we observed an association between CYP2B6
polymorphisms and response to bupropion treatment.
CYP2B6 is the primary metabolizing enzyme for bupropion
(as well as a secondary enzyme for nicotine metabolism)
thus the effectiveness of bupropion treatment in smoking
cessation may be determined by the rate of its metabolism,
as indicated by the CYP2B6 genotype. This is consistent
with previous studies, in which CYP2B6 polymorphisms
have been shown to affect the pharmacokinetics of
bupropion (Kirchheiner et al, 2003) and the likelihood of
achieving abstinence with bupropion in smoking cessation
trials (Lee et al, 2007). However, the polymorphisms
associated with response to bupropion in our study differed
from those identified in previous studies (which were not
successfully genotyped in our study), thus this does not
represent a true replication. A better understanding of
these associations may come from the identification and
characterization of additional functional alleles affecting
CYP2B6 activity or expression.
Overall Quit Success at 1 Year
The nicotinic receptor polymorphisms associated with
response to varenicline measured from weeks 9 to 12 were
not associated with continuous abstinence through the non-
treatment follow-up period (including all weeks 9–52).
During this period, no markers were significantly associated
with continuous abstinence in the varenicline-treated
smokers alone. In contrast, among the smokers treated
with bupropion, CYP2B6 polymorphisms were associated
with continuous abstinence from weeks 9 to 52, as well
as weeks 9 to 12. In fact, this association with CYP2B6
polymorphisms extended to all smokers, regardless of
treatment during the first 12 weeks. This may be due to a
broader effect of CYP2B6 on nicotine dependence, inde-
pendent of its role in bupropion metabolism. This
interpretation is consistent with a prior study identifying
an association of a functional CYP2B6 SNP with placebo
response in a bupropion clinical trial (Lee et al, 2007).
Alternatively, this genetic signal, although more proximate
to CYP2B6, may have a more direct effect on the adjacent
CYP2A6 locus, which is itself associated with continuous
abstinence from weeks 9 to 52. In addition to (or perhaps
because of) its role in nicotine metabolism, the CYP2A6
locus has also recently been found to be genetically
associated with nicotine dependence (The Tobacco and
Genetics Consortium, 2010; Thorgeirsson et al, 2010), and
phenotypic markers of nicotine metabolism rate have
reproducible associations with prospective smoking cessa-
tion (Ray et al, 2009). Continuous abstinence from weeks 9
to 52 also showed weaker associations with HTR3B and
CHRNA10 in the entire cohort. The association with HTR3B
may be explained relative to its association with relapse
to smoking (described below). The potential role of
CHRN10A in smoking cessation is less clear, although it
has been shown recently to be associated with nicotine
dependence in an African-American population (Saccone
et al, 2010a,b).
Relapse
We analyzed time to relapse to smoking in the subset of
subjects who successfully quit smoking while on treatment
during weeks 9–12, but relapsed during weeks 13–52.
Unexpectedly, the strongest associations with this pheno-
type were with polymorphisms in genes encoding the
serotonin receptors HTR3A and HTR3B. These genes were
originally included in our study to test whether they might
be related to nausea associated with varenicline treatment,
although they are expressed widely in the brain as well as
the gut (Niesler et al, 2008). Previous investigations using
an HTR3 antagonist, ondansetron, provide some insights
into why these loci may be important for relapse to
smoking. This medicine, originally developed to prevent
nausea (Cubeddu et al, 1990), has been shown to lower
cravings for alcohol and to ease the withdrawal symptoms
of opioid addictions (Chu et al, 2009; Johnson et al, 2002).
These results and our observations raise the intriguing
possibility that this serotonin receptor family may be
mediating its effects on relapse by impacting nicotine
withdrawal symptoms, suggesting a potential role for HTR3
inhibition in reducing such withdrawal symptoms, regard-
less of the initial treatment method.
Nausea
In this study, the primary locus associated with nausea
while attempting to quit smoking was the chr15q25 locus.
This locus, which includes genes encoding the b4, a5, and
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CHRNA3), is the predominant locus associated with
nicotine dependence (Amos et al, 2008; Hung et al, 2008;
Thorgeirsson et al, 2008). Carriers of risk alleles at this
locus are 30–40% more likely to become nicotine depen-
dent. As with the response to varenicline, the significant LD
in this region suggests that these associations are likely to
overlap with those for nicotine dependence, and thus
nausea experienced while quitting may be directly related
to nicotine dependence. Smokers who are more dependent
smoke more cigarettes per day and have a higher daily
intake of nicotine. The link between the chr15q25 locus
genes and nausea may be explained by tolerance, such that
those with a greater daily intake of nicotine are more
tolerant and therefore experience less nausea in response to
a nicotinic partial agonist such as varenicline. Alternatively,
incidence of nausea may be elevated in subjects with greater
risk for nicotine dependence because their nicotine intake is
greater before quitting, therefore exacerbating the symp-
toms of withdrawal on quitting. SNPs associated with
nausea are also linked to SNPs associated with the expres-
sion of CHRNA5, suggesting another mechanistic link
between nicotine dependence and nausea on quitting. For
subjects treated with varenicline, CHRNG, which encodes
the nAChRg subunit, is also associated with nausea. The
importance of this locus for nausea in the varenicline-
treated subjects is not clear, although recent studies have
identified associations with this region, which also includes
the CHRND gene, and nicotine dependence (Saccone et al,
2009), suggesting that the association with nausea may also
be driven by nicotine dependence.
Strengths and Limitations of This Study
The recent successes of genome-wide genetic association
studies have highlighted the need for large study popula-
tions in order to detect the small effect sizes often associated
with common genetic polymorphisms. However, most
pharmacogenomic studies conducted to date have involved
relatively small sample populations (Holmes et al, 2009).
Thus, the strengths of this analysis include: (a) its large
sample populationFthe largest such study to date of
bupropion for smoking cessation, the first (and therefore
also largest) pharmacogenetic analysis of varenicline, and
the first head-to-head analysis of these treatments; and (b)
the availability of robust phenotypic data from three
rigorously controlled clinical trials, providing a database
of patient data, adverse events, and, importantly, carbon
monoxide-confirmed smoking cessation outcomes. Limita-
tions of this analysis include: (a) a lack of generalizability
of the study findings to non-treatment-seeking smokersF
although the highly motivated (to quit smoking) population
recruited to these trials is the subset of the broader smoking
population to which pharmacogenetic tailoring approaches
would be provided, efforts to encourage non-motivated
smokers to quit may have different pharmacogenetic
characteristics; and (b) a lack of ethnic diversity among
the sample populationFthe candidate gene analysis was
limited to individuals of European ancestry in order to
avoid the effects of population stratification, and the
relatively small number of subjects of non-European
descent in our population prevented meaningful analysis
of this latter group. For this reason, the study findings
may not apply to populations of non-European descent.
These results will also require replication in independent
populations for validation. Ideally, larger populations will
also permit a genome-wide analysis of smoking cessation
pharmacogenetics, which could identify additional novel
loci affecting these phenotypes.
Future Perspectives
The goal of pharmacogenetic studies of smoking cessation
therapy is to help increase the likelihood of an individual
quitting smoking, and reduce the likelihood of adverse
effects of smoking cessation therapy by individualizing
treatment strategies according to genetic profile. Although
pharmacogenetic tests for some conditions have had
successful application in clinical practice (Mallal et al,
2008; Relling et al, 1999), this has not been without
challenges (Higgs et al, 2010; Ikediobi et al, 2009). Even
leaving aside issues of cost-effectiveness and concerns
around tests that could result in effective therapies being
withheld (Epstein et al, 2009), several important issues need
to be considered before pharmacogenetic testing for
selection of smoking cessation treatment becomes standard
clinical practice. Multiple genes and environmental factors
probably combine to influence the response to smoking
cessation therapies, yet most pharmacogenetic studies
currently focus on a limited set of alleles and/or single
genes and have limited power to account for gene–gene and
gene–environment interactions. The development of effec-
tive individualized treatments for smoking cessation will
likely require that future pharmacogenetic studies evaluate
these multifactorial interactions. However, despite such
challenges, access to larger populations and more detailed
information regarding the molecular genetics of nicotine
dependence and smoking cessation should lead to better
optimization of cessation approaches, and to a reduction in
overall smoking prevalence.
CONCLUSIONS
These data provide both novel and supporting evidence
for genetic loci contributing to smoking cessation and
therapeutic response. Importantly, different genetic signals
are associated with varenicline vs bupropion treatment
response, suggesting that future research may lead to clini-
cally useful markers to guide treatment decisions, resulting
in improved smoking cessation rates overall, and a reduc-
tion in smoking prevalence.
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